VAXART INC. - COMMON STOCK

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

30 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

16 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: VAXART INC. - COMMON STOCK

09 Apr 2025 09:47:15 By NetDania Notify

NetDania - New 12 months Low: VAXART INC. - COMMON STOCK

07 Apr 2025 09:45:42 By NetDania Notify

NetDania - New 12 months Low: VAXART INC. - COMMON STOCK

02 Apr 2025 09:45:01 By NetDania Notify

NetDania - New 12 months Low: VAXART INC. - COMMON STOCK

01 Apr 2025 10:11:35 By NetDania Notify

NetDania - New 12 months Low: VAXART INC. - COMMON STOCK

31 Mar 2025 09:47:06 By NetDania Notify

NetDania - New 12 months Low: VAXART INC. - COMMON STOCK

28 Mar 2025 10:08:59 By NetDania Notify

NetDania - New 12 months Low: VAXART INC. - COMMON STOCK

27 Mar 2025 11:26:13 By NetDania Notify

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

27 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

20 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20

13 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

11 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

05 Mar 2025 16:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: VAXART INC. - COMMON STOCK

24 Feb 2025 09:51:01 By NetDania Notify

Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

28 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

14 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

13 Jan 2025 19:55:00 By Nasdaq GlobeNewswire

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

02 Dec 2024 16:01:00 By Nasdaq GlobeNewswire

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 Nov 2024 08:00:00 By Nasdaq GlobeNewswire